Georgia Clinical Trials Report — July 2026

Georgia residents considering a clinical trial should act soon if they find a study that fits: 106 recruiting trials are expected to close within the next 90 days. Seventeen of those studies accept healthy volunteers, creating a limited window for people without a diagnosed condition. Enrollment projections can change, and screening may take time, so contacting a study team early is essential.

Georgia has 1,992 recruiting trials across 97 cities and 1,265 research sites. The state added 28 new trials in July, down from 47 in both May and June. Even with the slower opening pace, the number of active studies gives patients and volunteers options across major medical centers and communities beyond Atlanta.

Closing-soon studies create the most immediate opportunity

The closing-soon group covers both common and serious conditions. Stroke leads with 3 trials approaching their projected end dates. Acute myeloid leukemia, cancer overall, lupus nephritis, major depressive disorder, schizophrenia, asthma, atopic dermatitis, head and neck squamous cell carcinoma, and hematologic malignancies each have 2 closing-soon trials.

• Stroke — 3 closing-soon trials
• Acute myeloid leukemia and cancer — 2 each
• Lupus nephritis and major depressive disorder — 2 each
• Schizophrenia and asthma — 2 each
• Atopic dermatitis, head and neck squamous cell carcinoma, and hematologic malignancy — 2 each

Healthy volunteers should not assume that every study accepts people without a condition. Only 17 of the closing-soon trials list healthy volunteers, although 178 healthy-volunteer trials are recruiting statewide overall. People interested in contributing to research without seeking treatment should check eligibility now, particularly if they can travel to a site or participate in a study with broad enrollment.

July’s new studies emphasize drug development and major conditions

Fifteen of Georgia’s new trials are drug studies, making medication research the largest category. There are also 8 studies classified as other, 4 biological studies, and 3 behavioral and 3 device trials. The month’s new conditions include schizophrenia, relapsed or refractory multiple myeloma, Alzheimer’s disease and related disorders, ACL tears, aplastic anemias, brain tumors, brainstem glioma, caregiving, community health workers, and attitude research.

• Schizophrenia — 2 new trials
• Relapsed or refractory multiple myeloma — 2
• Alzheimer’s disease and related disorders, ACL tear, aplastic anemias, brain tumor, and brainstem glioma — 1 each
• Caregivers, community health workers, attitude, and related populations — 1 each

Several July openings stand out because of their late-stage development, large enrollment targets, or well-known sponsors:

• NCT07720271 — Novo Nordisk’s Phase 3 AMAZE 9 study is evaluating once-daily zenagamtide tablets against placebo in 950 people with excess body weight.
• NCT07735637 — AstraZeneca’s Phase 3 DURGA-6 study plans to enroll 750 transplant-eligible participants with newly diagnosed multiple myeloma and compares AZD0120 with autologous stem-cell transplantation.
• NCT07728188 — AbbVie is sponsoring a Phase 3 study of injected etentamig plus oral pomalidomide versus standard therapies in 520 adults with relapsed or refractory multiple myeloma.
• NCT07690371 — Nektar Therapeutics’ Phase 3 study is testing rezpegaldesleukin in 510 participants age 12 and older with moderate-to-severe atopic dermatitis.
• NCT07686263 — Karuna Therapeutics, a Bristol Myers Squibb company, is conducting a Phase 3 relapse-prevention study of KarXT in 472 adults with schizophrenia.
• NCT07684820 — Expedition Therapeutics’ Phase 2 COPD study will compare two doses of EXPD-101 with placebo over 52 weeks in 600 participants.

Georgia also has a notable vaccine opportunity for older adults. NCT07734649, sponsored by Sanofi, is a Phase 1/2 study of an RSV and human metapneumovirus vaccine candidate in 2,400 adults age 60 and older. The randomized study will examine immune response and safety. Another large new study, NCT07728123, is Westat’s Screen2Prevent project, which plans to involve 84,000 participants while evaluating targeted and universally offered HIV screening approaches in emergency departments.

Atlanta dominates new activity, with options across Georgia

Atlanta recorded 15 of the state’s 28 new trials, more than half of July’s openings. Decatur followed with 5, while Savannah added 3. Macon, Athens, Marietta, and Augusta each recorded 2 new trials. Kennesaw, La Grange, and Lilburn each had 1.

• Atlanta — 15 new trials
• Decatur — 5
• Savannah — 3
• Macon, Athens, Marietta, and Augusta — 2 each
• Kennesaw, La Grange, and Lilburn — 1 each

The distribution is concentrated in the Atlanta metropolitan area, especially Atlanta and nearby Decatur, Marietta, Kennesaw, and Lilburn. However, Savannah, Macon, Athens, Augusta, and La Grange show that opportunities extend beyond the capital region. Georgia residents should search by both condition and city, since a trial may be recruiting at only selected sites even when its overall enrollment target is large.

Children, older adults, and healthy volunteers have distinct openings

Six of July’s new trials include children, and 23 include older adults. One new study is female-only and one is male-only. These eligibility patterns may matter for families, older adults, and people seeking research designed for a specific population rather than a general adult study.

Industry sponsors accounted for 20 of the new trials, while 7 were classified as other and 1 as federally sponsored. Named sponsors include AstraZeneca, Antag Therapeutics, ArthroResearch, BrainChild Bio, Bristol Myers Squibb, Dren Bio, Emory University, and Expedition Therapeutics. The mix combines commercial drug development with academic and community-focused research.

New-trial activity has fluctuated during 2026: 42 trials opened in February, 54 in March, 38 in April, 47 in May, 47 in June, and 28 in July. The August figure currently stands at 6, which may change as the month develops. For patients with stroke, cancer, lupus nephritis, asthma, depression, schizophrenia, or skin disease—and for healthy adults interested in prevention or vaccine research—the next few weeks are a practical time to review eligibility before projected enrollment deadlines pass.